This is supported by the finding that IL-36α may exhibit anti-tumour effects in CRC progression [13], perhaps via activating adaptive T cell immune responses and recruiting CD3+ and CD8+ tumour infiltrating lymphocytes (TILs) [30]. The gene discussed is CD8A; the disease is colorectal carcinoma.